Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Dendreon presents phase I/II data on APC-8020 at ASH meeting

Dec. 16, 1998

Seattle Genetics initiates a phase I clinical trial of SGN-10

Dec. 16, 1998

AVI BioPharma reports encouraging clinical data from phase II Avicine study

Dec. 15, 1998

MAb-tyrosine kinase inhibitor immunoconjugate induces disease remission in ALL patients

Dec. 14, 1998

Novel GM-CSF-containing fusion toxin shows excellent antileukemia activity in mouse model

Dec. 14, 1998

Lorus Therapeutics announces final phase I/II pancreatic cancer trial data

Dec. 11, 1998

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Dec. 10, 1998

MGI Pharma expands prostate cancer study with MGI-114

Dec. 10, 1998

Techniclone initiates phase II trial for treatment of malignant glioma

Dec. 9, 1998

CMA-676 shows efficacy and excellent tolerability in patients with AML

Dec. 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...